Ok, here are my notes from the shareholders meeting. As I mentioned earlier, I don't think that I can add much more from the others that already posted. Overall I think it was a very good presentation from Dr. Missling. It was the same presentation that we have seen/heard before but the important part were the questions from the group. This type of questioning we don't get to see very often as many times it is part of a separate breakout session.
Session notes:
- 47M shares outstanding with 100M authorized
- Blank check will be approved ( from sidebar convo with Dr. M.)
- Alz Study 208 weeks most of the patients are still on drug.
- Will look at data next at 208 week mark for the original patients.
- My personal favorite, Major publication will publish data from the Phase 2A trail instead of presenting it at a scientific conf.
- Rett first patient has been dosed.
- Likes the idea of accelerated approval for PDD.
- From sidebar, the stock will stabilize once we have data from PDD and Rett. Only need a few key institutions to buy in to help the cause. I said it would be nice to have about 50% of the shares held by funds and the comment was that is not necessary, just a few key ones. They are in discussions with institutions all the time.
- Since Biogen failure seen increased activity in conversations with potential suiters.
- Extension of the trials are requested by the doctors and patients not built into the trial protocol.
- No need to have FDA / USA arm for Alz trial. Only needed if getting enough patients is an issue.
- Trial much cheaper in Australia vs. US.
- Plenty of product to sell with the $1M manufacturing run. If I remember correctly Dr. M stated they have enough product to handle all of Manhattan.
- There is no magic switch from P2B to a P3. It is one trial. I get the feeling from his answer that they continue to keep a low profile on what they are doing with labeling it a P2b/3. He stated one trial and after this trial they are done.
- From sidebar, blank check will only be used for an unwarranted acquisition. It should be enough just to have it to scare away any aggressive suiters who are looking to steal the company.
- Biogen MTA is over and no further testing going on.
If anyone else remembers differently please correct me.
Thanks everyone for their notes as well. Keep up the good info.
Market Data 
Markets 
AI
